A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.
Enoximone has been studied across 10 research domains including ❤️ Cardiovascular, 🫁 Respiratory, 🧠 Focus & Attention, 🌤️ Mood & Depression, ⚡ Energy & Fatigue. The primary research focus is ❤️ Cardiovascular with 57% of studies addressing this area.
The following compounds share molecular targets with Enoximone, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Enoximone is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.